Our Pricing

Mounjaro and Underactive Thyroid: UK Clinical Guidance

Published: 10 September 2026

Understanding the relationship between mounjaro and underactive thyroid is essential for patients with hypothyroidism considering tirzepatide for weight loss. Many people with underactive thyroid conditions struggle with weight management despite medication, and Mounjaro offers a clinically proven option—though specific considerations apply when combining it with thyroid hormone replacement therapy.

Can You Use Mounjaro With Underactive Thyroid?

Mounjaro and underactive thyroid conditions can generally be managed together safely, subject to prescriber approval. Hypothyroidism itself is not listed as a contraindication to tirzepatide treatment in MHRA guidance [1]. However, patients with underactive thyroid must have their condition adequately controlled on levothyroxine or other thyroid replacement therapy before starting Mounjaro.

Clinical assessment by a UK prescriber will evaluate your thyroid function tests (TSH, T4 levels), current thyroid medication dose, and overall metabolic stability. Weight loss from Mounjaro may alter your thyroid hormone requirements over time, so ongoing monitoring with your GP or endocrinologist remains essential throughout treatment [2].

Mounjaro and Underactive Thyroid: Drug Interactions

There are no direct pharmacological interactions between mounjaro and underactive thyroid medications like levothyroxine. Tirzepatide does not interfere with thyroid hormone absorption or metabolism at a molecular level [3]. However, because Mounjaro slows gastric emptying, timing of thyroid medication may require adjustment.

Levothyroxine is typically taken on an empty stomach first thing in the morning, 30-60 minutes before food. This timing should be maintained while using Mounjaro. Some patients report altered absorption patterns during initial weeks of tirzepatide treatment due to gastrointestinal effects, so thyroid function should be rechecked 6-8 weeks after starting Mounjaro to ensure TSH levels remain stable [4].

Monitoring Thyroid Levels During Mounjaro Treatment

As you lose weight on Mounjaro, your thyroid hormone requirements may decrease. In clinical practice, some patients with underactive thyroid require levothyroxine dose reductions as their body weight normalises and metabolic demand changes. Regular blood tests—ideally every 8-12 weeks initially—help ensure thyroid hormone levels remain optimal throughout your weight loss journey.

Weight Loss Effectiveness: Mounjaro and Underactive Thyroid

Clinical trials of tirzepatide did not exclude participants with well-controlled hypothyroidism, and real-world evidence suggests mounjaro and underactive thyroid patients achieve comparable weight loss outcomes to those without thyroid conditions [5]. In the SURMOUNT-1 trial, participants taking 15mg tirzepatide lost an average of 20.9% body weight over 72 weeks.

Patients with underactive thyroid may experience slightly slower initial weight loss if their condition is suboptimally treated, as hypothyroidism itself can reduce metabolic rate. Ensuring your TSH is within the optimal range (typically 0.5-2.5 mIU/L for weight management) before starting Mounjaro maximises treatment effectiveness. At Cured Pharmacy, our prescribers assess thyroid control as part of the clinical consultation, with Mounjaro available from £124.99 following approval.

Optimising Results With Hypothyroidism

To achieve best results when combining mounjaro and underactive thyroid treatment, maintain consistent levothyroxine dosing, attend regular thyroid monitoring appointments, and report any symptoms of over- or under-replacement (palpitations, fatigue, temperature sensitivity) to your healthcare provider promptly. Nutritional adequacy—particularly iodine and selenium intake—also supports thyroid health during weight loss.

Safety Considerations: Mounjaro and Underactive Thyroid Conditions

The primary safety concern with mounjaro and underactive thyroid relates to a different thyroid condition: medullary thyroid carcinoma (MTC). Tirzepatide carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans [6]. Patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not use Mounjaro.

Standard hypothyroidism (autoimmune or post-ablative) does not increase MTC risk and is not a contraindication to tirzepatide. However, if you have a history of thyroid nodules or abnormal thyroid ultrasound findings, your prescriber may request recent imaging or specialist clearance before approving Mounjaro treatment.

Starting Mounjaro With Underactive Thyroid: Clinical Process

When assessing suitability for mounjaro and underactive thyroid patients, UK prescribers require recent thyroid function test results (ideally within 3-6 months), confirmation of your current levothyroxine dose, and evidence of stable thyroid control. The online consultation at Cured Pharmacy includes specific questions about thyroid history and current medication.

If approved, you'll start on Mounjaro 2.5mg weekly, with dose escalation every 4 weeks as tolerated. Your thyroid medication continues unchanged initially, but you should arrange thyroid monitoring with your GP at 6-8 weeks, then every 12 weeks. Report any symptoms suggesting thyroid imbalance—unexplained fatigue, heart palpitations, or temperature intolerance—to your healthcare provider promptly [7].

Prescription Requirements and Approvals

All Mounjaro prescriptions require clinical assessment by a UK-registered prescriber. The consultation evaluates your BMI, weight loss history, comorbidities including thyroid conditions, and current medications. Treatment is subject to prescriber approval based on individual clinical suitability and absence of contraindications.

Mounjaro and Underactive Thyroid: UK Pricing and Access

At Cured Pharmacy, mounjaro and underactive thyroid patients can access tirzepatide from £124.99 following online clinical assessment. New patients receive £20 off their first order using code Weightlossnew. Pricing includes the medication, UK prescriber consultation, and discreet home delivery.

Treatment typically continues for 6-12 months or longer depending on weight loss goals and clinical response. Regular thyroid monitoring (blood tests) should be arranged through your NHS GP at no additional cost. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team provide ongoing support throughout your treatment journey, ensuring safe coordination with your thyroid medication [8].

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 10 September 2026]
2. Pearce, S. H., Brabant, G., Duntas, L. H., Monzani, F., Peeters, R. P., Razvi, S., & Wemeau, J. L. (2013). 2013 ETA Guideline: Management of subclinical hypothyroidism. European Thyroid Journal, 2(4), 215-228. [accessed 10 September 2026]
3. Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 21(1), 169. [accessed 10 September 2026]
4. Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Delle Fave, G., & Annibale, B. (2006). Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. New England Journal of Medicine, 354(17), 1787-1795. [accessed 10 September 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Bunck, M. C. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 10 September 2026]
6. Gier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012). Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras G12D mouse model. Diabetes, 61(5), 1250-1262. [accessed 10 September 2026]
7. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. NICE. [accessed 10 September 2026]
8. General Pharmaceutical Council. (2023). Standards for registered pharmacies. GPhC. [accessed 10 September 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.